Neurodegenerative diseases have a multitude of factors contributing to their pathogenesis. In the first of our Weekly Gene features covering pathogenic genes of neurodegenerative diseases, we review the functionality of TARDBP. This review, as well as the upcoming Weekly Gene articles, aim to help researchers explore potential therapeutics for neurogenerative diseases.
Read More ›
It is well known that genes play a major role in the pathogenesis of neurodegenerative diseases. There have been major efforts in biomedical research to learn about disease-related genes, which has led to highly targeted therapeutics for several diseases that were previously untreatable. In this article, we review the functionality of SNCA and explore its role in targeted gene therapy for neurodegenerative diseases, presenting brief technical insights on the state of SNCA gene research.
Read More ›
Huntington's disease (HD) is a rare, progressive brain disorder that is inherited in an autosomal dominant manner - this disorder is caused by a defective huntingtin (HTT) protein that changes the brain, causing patients to experience problems with behavior, thinking and involuntary movements.
Read More ›
Since IL17A plays an important role in infectious diseases, inflammatory, autoimmune diseases and cancer studies, IL17A has become a hot research target for many studies. In this Gene of the Week article, we have collected some insights on IL17A research progress and development trends, aiming to inspire even more scientific innovations.
Read More ›
Spinal muscular atrophy (SMA) is a genetic disease that involves the loss of motor neurons in the spinal cord, which affects the central nervous system, peripheral nervous system, and voluntary muscle movement. The primary pathogenic gene of spinal muscular atrophy is the survival of motor neuron 1 (SMN1) gene, mutations of which cause a deficiency of SMN motor neuron protein – ultimately resulting in Chromosome 5 SMA, the most common form of SMA.
Read More ›
The SIRT3 gene plays an important role in the pathogenesis of metabolic, cardiovascular, and neurodegenerative diseases. In this article, we review the functionality of SIRT3 and explore its role in metabolism & cardiovascular disease studies - bringing together insights to SIRT3 gene research developments to provide inspiration for your scientific innovation.
Read More ›
Several mutations in APOE (Apolipoprotein E) have been identified to not only increase the risk of developing AD, but other neurological and cardiovascular diseases. As scientists continue to evaluate potential therapies for AD, we hope to provide insights into various genes, related pathways, and research accomplishments in every Gene of the Week article. Herein, we summarize the current research progress on APOE functionality and review its role in Alzheimer's disease (AD).
Read More ›
Specific mutations in TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) have been confirmed to increase the risk of developing late-onset AD. Here, we review the current data detailing the function of TREM2 and its role in Alzheimer's disease (AD).
Read More ›
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, which is affecting 20 to 30 million individuals worldwide now. Currently, no effective therapies to treat or cure this disease were developed. In this review, we discuss the current research and understanding of the PSEN1 gene and its mutation in causing familial Alzheimer's disease (FAD).
Read More ›
It is well known that genes play a major role in many human diseases - for this reason they are an important research topic in the field of life science and medicine. How can the public quickly grasp the recent research on disease-related genes, when the only resources out about them are long complex academic journals? To save the time and energy of researchers, Cyagen has launched its new project -‘Gene of the Week’...
Read More ›
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy